Naoki Haratake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Naoki Haratake has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Atrayee Bhattacharya
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
48 shared publications - Atsushi Fushimi
Division of Breast and Endocrine Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan
48 shared publications - Donald Kufe
Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts
48 shared publications - Mark D. Long
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
48 shared publications - Nami Yamashita
Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
48 shared publications - Tatsuaki Daimon
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States
48 shared publications
Latest Publications
- 18 August 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56  (11) , 1395-1403
Clinical significance of spread through air spaces according to EGFR mutation status in lung adenocarcinoma
Objectives: Spread through air spaces (STAS) is a poor prognostic pathological feature recently included as a histological factor in the ninth edition of the TNM (tumor, node, and metastasis) classification. However, its clinical significance in lung adenocarcinoma with epidermal growth factor receptor (EGFR) gene mutations remains unclear. Here, we aimed to evaluate the clinical significance of STAS according to EGFR mutation status. Methods: We retrospectively reviewed 347 patients with completely resected pathological stage 0–IIIB lung adenocarcinoma who were evaluated for both STAS and EGFR mutations between 2015 and 2022. We investigated the association between clinicopathological features and STAS and analyzed its prognostic relevance based on EGFR mutation status. Results: STAS and EGFR mutations were present in 85 (24.5%) and 178 (51.3%) patients, respectively. In patients with EGFR-mutated lung adenocarcinoma, STAS was significantly more prevalent in those with exon 19 deletions than those with the L858R mutation (P = .012). STAS was significantly markedly associated with poorer recurrence-free and overall survival in patients both with (P < .001 and P < .001, respectively) and without (P = .003 and P = .023, respectively) EGFR mutations. Multivariable analysis revealed that STAS was an independent prognostic factor for recurrence-free and overall survival in patients with EGFR mutations (P < .001 and P = .020, respectively). However, STAS was not an independent predictor in patients without EGFR mutations. Conclusions: STAS is a key pathological feature of lung adenocarcinoma and holds considerable clinical relevance, particularly in EGFR-mutated lung adenocarcinoma.
- 18 August 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56  (11) , 1395-1403
Clinical significance of spread through air spaces according to EGFR mutation status in lung adenocarcinoma
Objectives: Spread through air spaces (STAS) is a poor prognostic pathological feature recently included as a histological factor in the ninth edition of the TNM (tumor, node, and metastasis) classification. However, its clinical significance in lung adenocarcinoma with epidermal growth factor receptor (EGFR) gene mutations remains unclear. Here, we aimed to evaluate the clinical significance of STAS according to EGFR mutation status. Methods: We retrospectively reviewed 347 patients with completely resected pathological stage 0–IIIB lung adenocarcinoma who were evaluated for both STAS and EGFR mutations between 2015 and 2022. We investigated the association between clinicopathological features and STAS and analyzed its prognostic relevance based on EGFR mutation status. Results: STAS and EGFR mutations were present in 85 (24.5%) and 178 (51.3%) patients, respectively. In patients with EGFR-mutated lung adenocarcinoma, STAS was significantly more prevalent in those with exon 19 deletions than those with the L858R mutation (P = .012). STAS was significantly markedly associated with poorer recurrence-free and overall survival in patients both with (P < .001 and P < .001, respectively) and without (P = .003 and P = .023, respectively) EGFR mutations. Multivariable analysis revealed that STAS was an independent prognostic factor for recurrence-free and overall survival in patients with EGFR mutations (P < .001 and P = .020, respectively). However, STAS was not an independent predictor in patients without EGFR mutations. Conclusions: STAS is a key pathological feature of lung adenocarcinoma and holds considerable clinical relevance, particularly in EGFR-mutated lung adenocarcinoma.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S9 and Tables S1-S4. from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
S1. Silencing MUC1-C downregulates IRF1 expression in TNBC cells. S2. Effects of silencing MUC1-C on TNBC cells. S3. MUC1-C is necessary for PBRM1 expression A and B. S4. MUC1-C forms a direct complex with IRF1 that activates type I and II ISGs. S5. Common genes regulated in cells silenced for MUC1, IRF1, and PBRM1. S6. Silencing MUC1-C, IRF1, and PBRM1 downregulated IDO1 and WARS in TNBC cells. S7. Silencing of MUC1-C, IRF1, and PBRM1 downregulates RIG-I and MDA5 in TNBC cells. S8. Silencing MUC1-C, IRF1, and PBRM1 downregulates ISG15 expression in TNBC cells. S9. Effects of silencing IRF1 and PBRM1 on BT-549 mammosphere formation and GO-203 treatment on the viability of olaparib-resistant MDA-MB-436RR cells. Table S1. Primers used for qRT-PCR. Table S2. Primers used for ChIP-qPCR and DNase I chromatin accessibility assays. Table S3. Common downregulated 196 DEGs in BT-549 cells with silencing of MUC1, IRF1, and PBRM1. Table S4. Overlapping IFN-pathway genes downregulated in cells with MUC1-C, PBRM1, and IRF1 silencing.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S9 and Tables S1-S4. from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
S1. Silencing MUC1-C downregulates IRF1 expression in TNBC cells. S2. Effects of silencing MUC1-C on TNBC cells. S3. MUC1-C is necessary for PBRM1 expression A and B. S4. MUC1-C forms a direct complex with IRF1 that activates type I and II ISGs. S5. Common genes regulated in cells silenced for MUC1, IRF1, and PBRM1. S6. Silencing MUC1-C, IRF1, and PBRM1 downregulated IDO1 and WARS in TNBC cells. S7. Silencing of MUC1-C, IRF1, and PBRM1 downregulates RIG-I and MDA5 in TNBC cells. S8. Silencing MUC1-C, IRF1, and PBRM1 downregulates ISG15 expression in TNBC cells. S9. Effects of silencing IRF1 and PBRM1 on BT-549 mammosphere formation and GO-203 treatment on the viability of olaparib-resistant MDA-MB-436RR cells. Table S1. Primers used for qRT-PCR. Table S2. Primers used for ChIP-qPCR and DNase I chromatin accessibility assays. Table S3. Common downregulated 196 DEGs in BT-549 cells with silencing of MUC1, IRF1, and PBRM1. Table S4. Overlapping IFN-pathway genes downregulated in cells with MUC1-C, PBRM1, and IRF1 silencing.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
Targeting MUC1-C in TNBC CSCs inhibits self-renewal capacity and circumvents DNA damage resistance. A, BT-549/tet-MUC1shRNA cells were treated with vehicle or DOX for 7 days and then assayed for tumorsphere formation in the absence and presence of 0.2 μmol/L CBDCA for 7 days (A, top); scale bar, 100 μm. The results (mean ± SD of 3 biological replicates) are expressed as the number of mammospheres (A, lower). B, BT-549/tet-MUC1shRNA mammospheres treated with vehicle or DOX in the absence and presence of 2 μmol/L CBDCA for 2 days were assayed by ICC analysis for visualization of γH2AX foci; scale bar, 50 μm. C, BT-549 cells treated with vehicle or 0.75 μmol/L GO-203 in the absence and presence of 0.2 μmol/L CBDCA were assayed for mammosphere formation at 8 days (top); scale bar, 100 μm. The results (mean ± SD of 3 biological replicates) are expressed as the number of mammospheres (bottom).D, BT-549 mammospheres treated with vehicle or 2.5 μmol/L GO-203 in the absence and presence of 2 μmol/L CBDCA for 2 days were assayed by ICC analysis for visualization of γH2AX foci; scale bar, 50 μm. E, Lysates from parental MDA-MB-436 and olaparib-resistant MDA-MB-436RR cells were immunoblotted with antibodies against the indicated proteins. F, MDA-MB-436RR cells treated with 5 μmol/L GO-203 for 2 days were immunoblotted with antibodies against the indicated proteins. G, MDA-MB-436RR cells treated with vehicle or 5 μmol/L GO-203 were assayed for mammosphere formation at 7 days (left); scale bar, 100 μm. The results (mean±SD of 3 biological replicates) are expressed as the number of mammospheres (right). H, MDA-MB-436RR mammospheres treated with vehicle or 2.5 μmol/L GO-203 for 2 days were assayed by ICC analysis for visualization of γH2AX foci; scale bar, 50 μm. I, Six-week-old nude mice were injected subcutaneously in the flank with 3×106 MDA-MB-436RR cells. Mice pair-matched into two groups when tumors reached 100 to 150 mm3 were treated intraperitoneally daily with PBS or GO-203 for 26 days. Tumor volumes are expressed as the mean±SEM for 6 mice. J, Lysates from tumors exposed for 5 days to GO-203 were immunoblotted with antibodies against the indicated proteins. *, P ≤ 0.05; ***, P ≤ 0.001.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
Targeting MUC1-C in TNBC CSCs inhibits self-renewal capacity and circumvents DNA damage resistance. A, BT-549/tet-MUC1shRNA cells were treated with vehicle or DOX for 7 days and then assayed for tumorsphere formation in the absence and presence of 0.2 μmol/L CBDCA for 7 days (A, top); scale bar, 100 μm. The results (mean ± SD of 3 biological replicates) are expressed as the number of mammospheres (A, lower). B, BT-549/tet-MUC1shRNA mammospheres treated with vehicle or DOX in the absence and presence of 2 μmol/L CBDCA for 2 days were assayed by ICC analysis for visualization of γH2AX foci; scale bar, 50 μm. C, BT-549 cells treated with vehicle or 0.75 μmol/L GO-203 in the absence and presence of 0.2 μmol/L CBDCA were assayed for mammosphere formation at 8 days (top); scale bar, 100 μm. The results (mean ± SD of 3 biological replicates) are expressed as the number of mammospheres (bottom).D, BT-549 mammospheres treated with vehicle or 2.5 μmol/L GO-203 in the absence and presence of 2 μmol/L CBDCA for 2 days were assayed by ICC analysis for visualization of γH2AX foci; scale bar, 50 μm. E, Lysates from parental MDA-MB-436 and olaparib-resistant MDA-MB-436RR cells were immunoblotted with antibodies against the indicated proteins. F, MDA-MB-436RR cells treated with 5 μmol/L GO-203 for 2 days were immunoblotted with antibodies against the indicated proteins. G, MDA-MB-436RR cells treated with vehicle or 5 μmol/L GO-203 were assayed for mammosphere formation at 7 days (left); scale bar, 100 μm. The results (mean±SD of 3 biological replicates) are expressed as the number of mammospheres (right). H, MDA-MB-436RR mammospheres treated with vehicle or 2.5 μmol/L GO-203 for 2 days were assayed by ICC analysis for visualization of γH2AX foci; scale bar, 50 μm. I, Six-week-old nude mice were injected subcutaneously in the flank with 3×106 MDA-MB-436RR cells. Mice pair-matched into two groups when tumors reached 100 to 150 mm3 were treated intraperitoneally daily with PBS or GO-203 for 26 days. Tumor volumes are expressed as the mean±SEM for 6 mice. J, Lysates from tumors exposed for 5 days to GO-203 were immunoblotted with antibodies against the indicated proteins. *, P ≤ 0.05; ***, P ≤ 0.001.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
MUC1-C/PBRM1/IRF1 complexes induce chromatin accessibility and expression of the RIG-I, MDA5, and ISG15 genes. A, Candidate pathway enrichment plot for the IFNA response in BT-549 cells silenced for MUC1-C, IRF1, and PBRM1. B and C, Genome browser snapshots of ATAC-seq data from the RIG-I (B) and MDA5 (C) PLSs in BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days (left). Chromatin was analyzed for accessibility by nuclease digestion (right). The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). D and E, Schema of the RIG-I (D) and MDA5 (E) genes with localization of a PLS upstream to the TSS. Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG, anti–MUC1-C, anti-IRF1 and anti-PBRM1. The DNA samples were amplified by qPCR with primers for the RIG-I (D) and MDA5 (E) PLS regions. The results (mean ± SD and individual values) are expressed as relative fold enrichment as compared with that obtained with IgG (assigned a value of 1). F, Chromatin from BT-549/CshRNA and BT-549/PBRM1shRNA cells was analyzed for accessibility of the RIG-I and MDA5 PLS regions by nuclease digestion. The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). G, Genome browser snapshots of ATAC-seq data from the ISG15 PLS in BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days (left). Chromatin was analyzed for accessibility by nuclease digestion (right). The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). H, Schema of the ISG15 gene with localization of a PLS upstream to the TSS. Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG, anti-MUC1-C, anti-IRF1, and anti-PBRM1. The DNA samples were amplified by qPCR with primers for the ISG15 PLS region. The results (mean ± SD and individual values) are expressed as relative fold enrichment as compared with that obtained with IgG (assigned a value of 1). I, Chromatin from BT-549/CshRNA and BT-549/PBRM1shRNA cells was analyzed for accessibility of the ISG15 PLS region by nuclease digestion. The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
MUC1-C/PBRM1/IRF1 complexes induce chromatin accessibility and expression of the RIG-I, MDA5, and ISG15 genes. A, Candidate pathway enrichment plot for the IFNA response in BT-549 cells silenced for MUC1-C, IRF1, and PBRM1. B and C, Genome browser snapshots of ATAC-seq data from the RIG-I (B) and MDA5 (C) PLSs in BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days (left). Chromatin was analyzed for accessibility by nuclease digestion (right). The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). D and E, Schema of the RIG-I (D) and MDA5 (E) genes with localization of a PLS upstream to the TSS. Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG, anti–MUC1-C, anti-IRF1 and anti-PBRM1. The DNA samples were amplified by qPCR with primers for the RIG-I (D) and MDA5 (E) PLS regions. The results (mean ± SD and individual values) are expressed as relative fold enrichment as compared with that obtained with IgG (assigned a value of 1). F, Chromatin from BT-549/CshRNA and BT-549/PBRM1shRNA cells was analyzed for accessibility of the RIG-I and MDA5 PLS regions by nuclease digestion. The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). G, Genome browser snapshots of ATAC-seq data from the ISG15 PLS in BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days (left). Chromatin was analyzed for accessibility by nuclease digestion (right). The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). H, Schema of the ISG15 gene with localization of a PLS upstream to the TSS. Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG, anti-MUC1-C, anti-IRF1, and anti-PBRM1. The DNA samples were amplified by qPCR with primers for the ISG15 PLS region. The results (mean ± SD and individual values) are expressed as relative fold enrichment as compared with that obtained with IgG (assigned a value of 1). I, Chromatin from BT-549/CshRNA and BT-549/PBRM1shRNA cells was analyzed for accessibility of the ISG15 PLS region by nuclease digestion. The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
MUC1, PBRM1, and IRF1 regulate similar gene sets that are shared with TNBC tumors. A, RNA-seq was performed in triplicate on BT-549 cells silenced for MUC1, PBRM1, and IRF1. The datasets were analyzed for effects of MUC1-C silencing on repressed and activated genes as depicted by the Volcano plots. B, Venn diagram depicting the overlap of 196 downregulated genes in BT-549 cells silenced for MUC1, IRF1, and PBRM1 (Supplementary Table S3). C, RNA-seq datasets from BT-549 cells silenced for MUC1, IRF1, and PBRM1 were analyzed with GSEA for enrichment distribution using the indicated IFN-related gene signatures. D, Heatmaps of 72 common genes between the HALLMARK INTERFERON GAMMA RESPONSE and HALLMARK INTERFERON ALPHA RESPONSE signatures in BT-549 cells silenced for MUC1, IRF1, and PBRM1. The row indicator shows the 45 common genes from the 196 DEGs identified in B (yellow, Supplementary Table S4). E, Common up- and downregulated IFN response genes (detectable 66 genes out of 72 genes) in MUC1-high versus MUC1-low TNBC tumors from the METABRIC and TCGA-BRCA datasets. The outline (gold/gray) represents common DEGs in BT549 cells identified in D. The red/gray/blue dot indicates significantly up/downregulated genes (MUC1high vs. MUC1low) in one or both of the TCGA-BRCA/METABRIC cohorts.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
MUC1, PBRM1, and IRF1 regulate similar gene sets that are shared with TNBC tumors. A, RNA-seq was performed in triplicate on BT-549 cells silenced for MUC1, PBRM1, and IRF1. The datasets were analyzed for effects of MUC1-C silencing on repressed and activated genes as depicted by the Volcano plots. B, Venn diagram depicting the overlap of 196 downregulated genes in BT-549 cells silenced for MUC1, IRF1, and PBRM1 (Supplementary Table S3). C, RNA-seq datasets from BT-549 cells silenced for MUC1, IRF1, and PBRM1 were analyzed with GSEA for enrichment distribution using the indicated IFN-related gene signatures. D, Heatmaps of 72 common genes between the HALLMARK INTERFERON GAMMA RESPONSE and HALLMARK INTERFERON ALPHA RESPONSE signatures in BT-549 cells silenced for MUC1, IRF1, and PBRM1. The row indicator shows the 45 common genes from the 196 DEGs identified in B (yellow, Supplementary Table S4). E, Common up- and downregulated IFN response genes (detectable 66 genes out of 72 genes) in MUC1-high versus MUC1-low TNBC tumors from the METABRIC and TCGA-BRCA datasets. The outline (gold/gray) represents common DEGs in BT549 cells identified in D. The red/gray/blue dot indicates significantly up/downregulated genes (MUC1high vs. MUC1low) in one or both of the TCGA-BRCA/METABRIC cohorts.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 7 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
MUC1 and PBRM1 associate with decreases in responsiveness of TNBC tumors to chemotherapy. A and B, Kaplan–Meier curves for relapse-free survival created by the public database and web application KM plotter (http://kmplot.com/ analysis/) based on the MUC1 (A) and PBRM1 (B) expression levels. Patients with TNBC were stratified with high (red) or low (black) expression of MUC1 and PBRM1. C and D, Representative MUC1-C staining in cell membrane (C) and cytosol/nuclear (D) of primary TNBC samples (magnifications, ×20). Insets highlight localization of MUC1-C expression in cancer cells (magnifications, ×100). E, TNBC tumors with cell membrane (left) and cytosol/nuclear (right) MUC1-C expression were stratified with sTIL levels in TNBC samples. F, Proposed model based on the present data demonstrating that MUC1-C induces PBRM1 expression and, in turn, binds to PBRM1. MUC1-C/PBRM1 complexes associate with (i) STAT1 in activating the IRF1 gene and (ii) IRF1 in activating STAT1 by increasing chromatin accessibility and their transcription. Induction of STAT1 and IRF1 expression contributes to a feed-forward circuit in which MUC1-C/PBRM1/STAT1 and MUC1-C/PBRM1/IRF1 complexes drive activation of genes in the type I and II IFN pathways. In this way, prolonged MUC1-C activation in settings of repetitive cycles of damage and repair promote chronic inflammation. A consequence of persistent MUC1-C activation and PBRM1-mediated chromatin remodeling is the establishment of IFN gene signatures that contribute to the CSC state and DNA damage resistance. DNA damage-induced inflammatory signaling is coupled to immune evasion, which in turn contributes to a MUC1-C/PBRM1-driven auto-inductive circuit that integrates a refractory state to treatment with genotoxic and immunotherapeutic agents. Figure created with BioRender.com. *, P ≤ 0.05.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 7 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
MUC1 and PBRM1 associate with decreases in responsiveness of TNBC tumors to chemotherapy. A and B, Kaplan–Meier curves for relapse-free survival created by the public database and web application KM plotter (http://kmplot.com/ analysis/) based on the MUC1 (A) and PBRM1 (B) expression levels. Patients with TNBC were stratified with high (red) or low (black) expression of MUC1 and PBRM1. C and D, Representative MUC1-C staining in cell membrane (C) and cytosol/nuclear (D) of primary TNBC samples (magnifications, ×20). Insets highlight localization of MUC1-C expression in cancer cells (magnifications, ×100). E, TNBC tumors with cell membrane (left) and cytosol/nuclear (right) MUC1-C expression were stratified with sTIL levels in TNBC samples. F, Proposed model based on the present data demonstrating that MUC1-C induces PBRM1 expression and, in turn, binds to PBRM1. MUC1-C/PBRM1 complexes associate with (i) STAT1 in activating the IRF1 gene and (ii) IRF1 in activating STAT1 by increasing chromatin accessibility and their transcription. Induction of STAT1 and IRF1 expression contributes to a feed-forward circuit in which MUC1-C/PBRM1/STAT1 and MUC1-C/PBRM1/IRF1 complexes drive activation of genes in the type I and II IFN pathways. In this way, prolonged MUC1-C activation in settings of repetitive cycles of damage and repair promote chronic inflammation. A consequence of persistent MUC1-C activation and PBRM1-mediated chromatin remodeling is the establishment of IFN gene signatures that contribute to the CSC state and DNA damage resistance. DNA damage-induced inflammatory signaling is coupled to immune evasion, which in turn contributes to a MUC1-C/PBRM1-driven auto-inductive circuit that integrates a refractory state to treatment with genotoxic and immunotherapeutic agents. Figure created with BioRender.com. *, P ≤ 0.05.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
MUC1-C regulates PBRM1 expression and function in activating the STAT1 and IRF1 genes. A, Genome browser snapshots of ATAC-seq data from the PBRM1 gene in BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days (left). Chromatin was analyzed for accessibility by nuclease digestion (right). The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). B, BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for the indicated days were analyzed for PBRM1 mRNA levels by qRT-PCR (left). The results (mean ± SD and individual values) are expressed as relative mRNA levels as compared with that obtained in control vehicle-treated cells (assigned a value of 1). Lysates were immunoblotted with antibodies against the indicated proteins (right). C, Schema of the PBRM1 gene with localization of a PLS downstream to the TSS. Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG, anti–MUC1-C and anti-IRF1. The DNA samples were amplified by qPCR with primers for the PBRM1 PLS region. The results (mean ± SD and individual values) are expressed as relative fold enrichment as compared with that obtained with IgG (assigned a value of 1). D, BT-549/CshRNA, BT-549/IRF1shRNA and BT-549/IRF1shRNA#2 cells were analyzed for PBRM1 mRNA levels by qRT-PCR (left). The results (mean ± SD and individual values) are expressed as relative mRNA levels as compared with that obtained in control vehicle-treated cells (assigned a value of 1). Lysates were immunoblotted with antibodies against the indicated proteins (right). E, Nuclear lysates from BT-549 cells were precipitated with a control IgG and anti–MUC1-C. Input proteins and precipitates were immunoblotted with antibodies against the indicated proteins. F, Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG and anti-PBRM1. The DNA samples were amplified by qPCR with primers for the indicated IRF1 and STAT1 regions. The results (mean ± SD and individual values) are expressed as fold-enrichment as compared with that obtained from control IgG-precipitated chromatin (assigned a value of 1). G, Genome browser snapshots of ATAC-seq data from the indicated IRF1 regions in BT-549/CshRNA and BT-549/PBRM1shRNA cells. Chromatin from the indicated IRF1 regions was analyzed for accessibility by nuclease digestion. The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). H, Genome browser snapshots of ATAC-seq data from the STAT1 PLS in BT-549/CshRNA and BT-549/PBRM1shRNA cells. Chromatin was analyzed for accessibility by nuclease digestion. The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
MUC1-C regulates PBRM1 expression and function in activating the STAT1 and IRF1 genes. A, Genome browser snapshots of ATAC-seq data from the PBRM1 gene in BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days (left). Chromatin was analyzed for accessibility by nuclease digestion (right). The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). B, BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for the indicated days were analyzed for PBRM1 mRNA levels by qRT-PCR (left). The results (mean ± SD and individual values) are expressed as relative mRNA levels as compared with that obtained in control vehicle-treated cells (assigned a value of 1). Lysates were immunoblotted with antibodies against the indicated proteins (right). C, Schema of the PBRM1 gene with localization of a PLS downstream to the TSS. Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG, anti–MUC1-C and anti-IRF1. The DNA samples were amplified by qPCR with primers for the PBRM1 PLS region. The results (mean ± SD and individual values) are expressed as relative fold enrichment as compared with that obtained with IgG (assigned a value of 1). D, BT-549/CshRNA, BT-549/IRF1shRNA and BT-549/IRF1shRNA#2 cells were analyzed for PBRM1 mRNA levels by qRT-PCR (left). The results (mean ± SD and individual values) are expressed as relative mRNA levels as compared with that obtained in control vehicle-treated cells (assigned a value of 1). Lysates were immunoblotted with antibodies against the indicated proteins (right). E, Nuclear lysates from BT-549 cells were precipitated with a control IgG and anti–MUC1-C. Input proteins and precipitates were immunoblotted with antibodies against the indicated proteins. F, Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG and anti-PBRM1. The DNA samples were amplified by qPCR with primers for the indicated IRF1 and STAT1 regions. The results (mean ± SD and individual values) are expressed as fold-enrichment as compared with that obtained from control IgG-precipitated chromatin (assigned a value of 1). G, Genome browser snapshots of ATAC-seq data from the indicated IRF1 regions in BT-549/CshRNA and BT-549/PBRM1shRNA cells. Chromatin from the indicated IRF1 regions was analyzed for accessibility by nuclease digestion. The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). H, Genome browser snapshots of ATAC-seq data from the STAT1 PLS in BT-549/CshRNA and BT-549/PBRM1shRNA cells. Chromatin was analyzed for accessibility by nuclease digestion. The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
MUC1-C drives chromatin accessibility and activation of IRF1 and STAT1. A, Genome browser snapshots of ATAC-seq data from the IRF1 gene in BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days. B, Chromatin was analyzed for accessibility by nuclease digestion. The results are expressed as the percentage of undigested chromatin (mean±SD and individual values). C, Schema of the IRF1 gene highlighting positioning of a promoter-like signature (PLS) and distal enhancer-like signatures (dELS) downstream (dELS-DN) and upstream (dELS-UP) to the TSS. Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG, anti–MUC1-C and anti-STAT1. The DNA samples were amplified by qPCR with primers for the indicated IRF1 regions. The results (mean ± SD and individual values) are expressed as fold-enrichment as compared with that obtained from control IgG-precipitated chromatin (assigned a value of 1). D and E, Genome browser snapshot of ATAC-seq data from the STAT1 PLS region in BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days (D). Chromatin was analyzed for accessibility by nuclease digestion (E). The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). F, Schema of the STAT1 gene with localization of a PLS upstream to the TSS. Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG, anti–MUC1-C and anti-IRF1. The DNA samples were amplified by qPCR with primers for the STAT1 PLS region. The results (mean±SD and individual values) are expressed as relative fold enrichment as compared with that obtained with IgG (assigned a value of 1). G, BT-549/CshRNA, BT-549/IRF1shRNA and BT-549/IRF1shRNA#2 cells were analyzed for IRF1 and STAT1 mRNA levels by qRT-PCR. The results (mean ± SD and individual values) are expressed as relative mRNA levels as compared with that obtained in CshRNA cells (assigned a value of 1). H, Lysates were immunoblotted with antibodies against the indicated proteins. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
MUC1-C drives chromatin accessibility and activation of IRF1 and STAT1. A, Genome browser snapshots of ATAC-seq data from the IRF1 gene in BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days. B, Chromatin was analyzed for accessibility by nuclease digestion. The results are expressed as the percentage of undigested chromatin (mean±SD and individual values). C, Schema of the IRF1 gene highlighting positioning of a promoter-like signature (PLS) and distal enhancer-like signatures (dELS) downstream (dELS-DN) and upstream (dELS-UP) to the TSS. Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG, anti–MUC1-C and anti-STAT1. The DNA samples were amplified by qPCR with primers for the indicated IRF1 regions. The results (mean ± SD and individual values) are expressed as fold-enrichment as compared with that obtained from control IgG-precipitated chromatin (assigned a value of 1). D and E, Genome browser snapshot of ATAC-seq data from the STAT1 PLS region in BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days (D). Chromatin was analyzed for accessibility by nuclease digestion (E). The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). F, Schema of the STAT1 gene with localization of a PLS upstream to the TSS. Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG, anti–MUC1-C and anti-IRF1. The DNA samples were amplified by qPCR with primers for the STAT1 PLS region. The results (mean±SD and individual values) are expressed as relative fold enrichment as compared with that obtained with IgG (assigned a value of 1). G, BT-549/CshRNA, BT-549/IRF1shRNA and BT-549/IRF1shRNA#2 cells were analyzed for IRF1 and STAT1 mRNA levels by qRT-PCR. The results (mean ± SD and individual values) are expressed as relative mRNA levels as compared with that obtained in CshRNA cells (assigned a value of 1). H, Lysates were immunoblotted with antibodies against the indicated proteins. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
MUC1-C/PBRM1/IRF1 complexes induce chromatin accessibility and expression of the IDO1 and WARS genes. A, Candidate pathway enrichment plot for the IFNG response and tryptophan metabolism in BT-549 cells silenced for MUC1-C, IRF1, and PBRM1. B, Schema of the IDO1 gene with localization of a PLS upstream to the TSS. Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG, anti-MUC1-C, anti-IRF1, and anti-PBRM1. The DNA samples were amplified by qPCR with primers for the IDO1 PLS region. The results (mean ± SD and individual values) are expressed as relative fold enrichment as compared with that obtained with IgG (assigned a value of 1). C, Schema of the WARS gene with localization of a PLS upstream to the TSS. Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG, anti–MUC1-C, anti-IRF1, and anti-PBRM1. The DNA samples were amplified by qPCR with primers for the WARS PLS region. The results (mean ± SD and individual values) are expressed as relative fold enrichment as compared with that obtained with IgG (assigned a value of 1). D and E, Genome browser snapshots of ATAC-seq data from the IDO1 (D) and WARS (E) PLS regions in BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days (left). Chromatin was analyzed for accessibility by nuclease digestion (right). The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). F and G, Chromatin from BT-549/CshRNA and BT-549/PBRM1shRNA cells was analyzed for accessibility of the IDO1 (F) and WARS (G) PLS regions by nuclease digestion. The results are expressed as the percentage of undigested chromatin (mean±SD and individual values). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
MUC1-C/PBRM1/IRF1 complexes induce chromatin accessibility and expression of the IDO1 and WARS genes. A, Candidate pathway enrichment plot for the IFNG response and tryptophan metabolism in BT-549 cells silenced for MUC1-C, IRF1, and PBRM1. B, Schema of the IDO1 gene with localization of a PLS upstream to the TSS. Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG, anti-MUC1-C, anti-IRF1, and anti-PBRM1. The DNA samples were amplified by qPCR with primers for the IDO1 PLS region. The results (mean ± SD and individual values) are expressed as relative fold enrichment as compared with that obtained with IgG (assigned a value of 1). C, Schema of the WARS gene with localization of a PLS upstream to the TSS. Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG, anti–MUC1-C, anti-IRF1, and anti-PBRM1. The DNA samples were amplified by qPCR with primers for the WARS PLS region. The results (mean ± SD and individual values) are expressed as relative fold enrichment as compared with that obtained with IgG (assigned a value of 1). D and E, Genome browser snapshots of ATAC-seq data from the IDO1 (D) and WARS (E) PLS regions in BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days (left). Chromatin was analyzed for accessibility by nuclease digestion (right). The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). F and G, Chromatin from BT-549/CshRNA and BT-549/PBRM1shRNA cells was analyzed for accessibility of the IDO1 (F) and WARS (G) PLS regions by nuclease digestion. The results are expressed as the percentage of undigested chromatin (mean±SD and individual values). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Data from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
The polybromo-1 (PBRM1) chromatin-targeting subunit of the SWI/SNF PBAF chromatin remodeling complex drives DNA damage resistance and immune evasion in certain cancer cells through mechanisms that remain unclear. STAT1 and IRF1 are essential effectors of type I and II IFN pathways. Here, we report that MUC1-C is necessary for PBRM1 expression and that it forms a nuclear complex with PBRM1 in triple-negative breast cancer (TNBC) cells. Analysis of global transcriptional (RNA-seq) and chromatin accessibility (ATAC-seq) profiles further demonstrated that MUC1-C and PBRM1 drive STAT1 and IRF1 expression by increasing chromatin accessibility of promoter-like signatures (PLS) on their respective genes. We also found that MUC1-C, PBRM1, and IRF1 increase the expression and chromatin accessibility on PLSs of the (i) type II IFN pathway IDO1 and WARS genes and (ii) type I IFN pathway RIG-I, MDA5, and ISG15 genes that collectively contribute to DNA damage resistance and immune evasion. In support of these results, targeting MUC1-C in wild-type BRCA TNBC cells enhanced carboplatin-induced DNA damage and the loss of self-renewal capacity. In addition, MUC1-C was necessary for DNA damage resistance, self-renewal, and tumorigenicity in olaparib-resistant BRCA1-mutant TNBC cells. Analysis of TNBC tumors corroborated that (i) MUC1 and PBRM1 are associated with decreased responsiveness to chemotherapy and (ii) MUC1-C expression is associated with the depletion of tumor-infiltrating lymphocytes (TIL). These findings demonstrate that MUC1-C activates PBRM1, and thereby chromatin remodeling of IFN-stimulated genes that promote chronic inflammation, DNA damage resistance, and immune evasion.Implications:MUC1-C is necessary for PBRM1-driven chromatin remodeling in chronic activation of IFN pathway genes that promote DNA damage resistance and immunosuppression.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
The polybromo-1 (PBRM1) chromatin-targeting subunit of the SWI/SNF PBAF chromatin remodeling complex drives DNA damage resistance and immune evasion in certain cancer cells through mechanisms that remain unclear. STAT1 and IRF1 are essential effectors of type I and II IFN pathways. Here, we report that MUC1-C is necessary for PBRM1 expression and that it forms a nuclear complex with PBRM1 in triple-negative breast cancer (TNBC) cells. Analysis of global transcriptional (RNA-seq) and chromatin accessibility (ATAC-seq) profiles further demonstrated that MUC1-C and PBRM1 drive STAT1 and IRF1 expression by increasing chromatin accessibility of promoter-like signatures (PLS) on their respective genes. We also found that MUC1-C, PBRM1, and IRF1 increase the expression and chromatin accessibility on PLSs of the (i) type II IFN pathway IDO1 and WARS genes and (ii) type I IFN pathway RIG-I, MDA5, and ISG15 genes that collectively contribute to DNA damage resistance and immune evasion. In support of these results, targeting MUC1-C in wild-type BRCA TNBC cells enhanced carboplatin-induced DNA damage and the loss of self-renewal capacity. In addition, MUC1-C was necessary for DNA damage resistance, self-renewal, and tumorigenicity in olaparib-resistant BRCA1-mutant TNBC cells. Analysis of TNBC tumors corroborated that (i) MUC1 and PBRM1 are associated with decreased responsiveness to chemotherapy and (ii) MUC1-C expression is associated with the depletion of tumor-infiltrating lymphocytes (TIL). These findings demonstrate that MUC1-C activates PBRM1, and thereby chromatin remodeling of IFN-stimulated genes that promote chronic inflammation, DNA damage resistance, and immune evasion.Implications:MUC1-C is necessary for PBRM1-driven chromatin remodeling in chronic activation of IFN pathway genes that promote DNA damage resistance and immunosuppression.